It is a plasmodia. Marshall
James Holmes wrote: > Does the causative organism of Malaria have a spore form? I thought > it was a protozoan. Don't have time to research it now.JOH > > -----Original Message----- > From: Marshall Dudley [mailto:[email protected]] > Sent: Thursday, September 04, 2003 8:40 AM > To: [email protected] > Subject: Re: CS>A Good Read > > I spoke with the president of American Biotech. Their > patent on making the silver is at: > > http://patft.uspto.gov/netacgi/nph > > Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1=6214299.WKU.&OS=PN/6214299&RS=PN/6214299 > > It looks basically like the SilverPro method with one > electrode submerged, and with stirring. > > He claims that the CS thus made will not kill spores (as we > determined), but that they have some type of secret process > that then converts the silver particles to be much more > effective, and that after this process that takes hours, it > will kill spores without having to germinate them. > > They add nothing to the CS, it is pure water and silver. > > Marshall > > [email protected] wrote: > > > > > > > Hello List, > > > > Clifton Mining (CFTN-OTC) and American Biotech produce a > > colloidal silver compound that arrests the effects of > > malaria. The mosquito-born fever kills 2.7 million people > > a year, mostly African children. The world spends $300 > > million a year on malaria control and a WHO progress > > report on the $700 million Roll Back Malaria campaign > > conducted over the past two years has achieved little. UN > > Secretary General Kofi Annan is from Ghana, where > > successful tests have been completed, which in hospital > > trials shows that American Biotech and Clifton Mining's > > colloidal silver product ASAP arrests the effects of > > malaria. The two companies' representative met this week > > with WHO executives to discuss the possible use of ASAP > > via the World Health Organization. Malaria costs the > > African economy $12 billion a year. > > > > Clifton Mining Company (OTC: CFTN) > > Alpine, Utah: November 11th, 2002. Clifton Mining Company > > (OTC: CFTN) is pleased to announce that American Biotech > > Labs, a company in which Clifton owns approximately 30% > > has finished the approval process with the U.S. EPA and > > expects to get full hospital approval in the next few > > weeks. > > > > The Testing > > > > In the test work for the EPA hospital approval, the ASAP > > Solution® had to kill hundreds of thousands of some of the > > deadliest types of bacteria found in the United States > > within minutes, and it proved able to do so. There were > > approximately 1600 individual bacterial tests in just one > > series alone. American Biotech's product was able to pass > > all the tests. > > > > The Hospital Approval > > > > American Biotech Labs expects to get the full hospital > > disinfectant approval within the next 15-45 days. The > > approval will open the door to sell the highly effective, > > yet non-toxic disinfectant to thousands of hospitals, > > clinics, rest homes, and other healthcare facilities > > worldwide. Management expects sales of the new > > disinfectant to possibly begin as soon as January 2003. > > Said Keith Moeller, V.P., "This will be a very important > > product for the market. Because this product is non-toxic > > and yet highly effective at killing even the MRSA super > > bacteria, we expect sales to boom worldwide. Unlike other > > disinfectants, this product can be used in and around > > patients to kill bacteria with no adverse effect. It is so > > safe that it could be sprayed right on the skin or even > > consumed orally with no adverse consequences." > > > > Malaria Testing/Drug Approval > > > > A new human trial specifically testing ASAP's > > effectiveness on malaria is under way in Ghana, West > > Africa. In the first two tests, 19 people who had been > > diagnosed with malaria were treated with the ASAP > > Solution. All 19 people (mostly children) were reported by > > the doctors as being fully recovered within just seven > > days. The latest malaria tests should be completed within > > the next 60 days. With no reported failures, the human > > tests have gone so well that the official Food and Drug > > Board of Ghana has already approved the ASAP Solution® for > > drug registration. Recent West African trials also tested > > the product as a treatment for fungal skin infections, > > vaginal infections, urinary tract infections, tonsillitis, > > pharingitis, some sexually transmitted diseases, > > conjunctivitis, upper respiratory tract infections, nasal > > and sinus problems, etc. In almost every human case tested > > so far, full recovery was reached in just 1-7 days. > > > > http://www.kitco.com/ind/Chapman/nov122002.html > > > > Michael > > > > > > > > > > > > >
